New Immune-Boosting drug enters human testing for tough cancers
NCT ID NCT04840394
Summary
This early-stage study tested a new drug called BDB001, which aims to activate the immune system to fight cancer. It was given to people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose, both when used alone and when combined with another immunotherapy drug (pembrolizumab).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
START
San Antonio, Texas, 78229, United States
-
START MidWest
Grand Rapids, Michigan, 49501, United States
Conditions
Explore the condition pages connected to this study.